Navigation Links
iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company

Study Includes iCardiac's Highly Automated QT(sm) Solution

Rochester, New York (PRWEB) April 1, 2009 -- iCardiac Technologies announced today that its advanced cardiac safety biomarkers were used successfully in a clinical study to model the effect of a serious disease on the heart's repolarization process.

The repolarization biomarkers, captured on a continuous electrocardiogram, played a key role in helping a leading pharmaceutical company to model the effects of disease on cardiac repolarization. The information provided by iCardiac's advanced morphological biomarkers enables drug developers to separate reliably the cardiac effects triggered by experimental drugs.

"This is an important step for cardiac safety testing," said iCardiac's Co-Founder and Executive Vice President Sasha Latypova. "Up until now there has not been a means for pharmaceutical companies to separate conclusively QT prolongation that originates with the disease state from that which stems from the drug being tested."

iCardiac's advanced ECG-based biomarkers enable a comprehensive evaluation of cardiac repolarization morphology and dynamics. The repolarization process - represented by what is called the QT interval, as measured on an ECG - is the brief period of time between two heart beats and is known to be a vulnerable time for arrhythmia induction. In rare instances, drug-induced arrhythmias can lead to sudden cardiac death.

iCardiac's COMPAS software platform performs digital quantification of repolarization abnormalities and enables measurement of subtle differences in ECG signals that may indicate arrhythmia predisposition. iCardiac's validation studies conducted at the University of Rochester have demonstrated that quantification of such morphological changes complement and improve upon information gathered from QT interval studies.

The study also included iCardiac's validated Highly Automated QT analysis. The highly automated solution combines advanced ECG signal processing algorithms developed over the past decade with a robust quality assurance process conducted by cardiologists. It has been validated in over 10 clinical QT studies and has been accepted by the FDA as equivalent to the manual evaluation of ECGs in Through QT studies.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit:


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
3. Saddam Lawyer Applies for Pardon for Dr Crippen
4. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
5. Leading Middle East Cancer Hospital Acquires Advanced Radiotherapy Capability from Varian Medical Systems
6. Sigma-Aldrich Streamlines Access to Advanced Stem Cell Research Portfolio and Opens Stem Cell Biology Community Through New Web Portal
7. ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability
8. Advanced Life Sciences Receives Notice of Planned Cethromycin Review by FDA Advisory Committee
9. Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
10. Advanced Life Sciences Announces 2008 Fourth Quarter and Full Year Financial Results
11. Nasdaq Panel Grants Advanced Life Sciences Request for Continued Listing on Nasdaq Stock Market
Post Your Comments:
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at . ...
Breaking Biology Technology:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):